Patent ID: 11926668
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 25:
26. A method of treating non-small cell lung cancer (NSCLC) or increasing the survival of a patient with NSCLC, comprising:
(a) selecting a patient NSCLC wherein: (i) the patient has not been previously treated with a systemic treatment for NSCLC (ii) the patient has tested negative for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and ROS1 fusions; and (iii) the NSCLC is locally advanced and the patient is not a candidate for definitive chemoradiation, or the NSCLC is metastatic; and
(b) administering to the patient one or more doses of platinum-based chemotherapy in combination with one or more doses of a therapeutically effective amount of an antibody that binds specifically to PD-1, thereby treating NSCLC in the patient;
wherein the antibody comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8; and
the antibody is administered intravenously every three weeks at a dose of 350 mg.